Neuronal Serpina3n is an endogenous protector against blood brain barrier damage following cerebral ischemic stroke

Fengshi Li,Yueman Zhang,Ruqi Li,Yan Li,Shenghao Ding,Jianpo Zhou,Tianchen Huang,Chen Chen,Bingwei Lu,Weifeng Yu,Johannes Boltze,Peiying Li,Jieqing Wan
DOI: https://doi.org/10.1177/0271678X221113897
2022-12-02
Abstract:Journal of Cerebral Blood Flow &Metabolism, Ahead of Print. Ischemic stroke results in blood-brain barrier (BBB) disruption, during which the reciprocal interaction between ischemic neurons and components of the BBB appears to play a critical role. However, the underlying mechanisms for BBB protection remain largely unknown. In this study, we found that Serpina3n, a serine protease inhibitor, was significantly upregulated in the ischemic brain, predominantly in ischemic neurons from 6 hours to 3 days after stroke. Using neuron-specific adeno-associated virus (AAV), intranasal delivery of recombinant protein, and immune-deficient Rag1−/− mice, we demonstrated that Serpina3n attenuated BBB disruption and immune cell infiltration following stroke by inhibiting the activity of granzyme B (GZMB) and neutrophil elastase (NE) secreted by T cells and neutrophils. Furthermore, we found that intranasal delivery of rSerpina3n significantly attenuated the neurologic deficits after stroke. In conclusion, Serpina3n is a novel ischemic neuron-derived proteinase inhibitor that counterbalances BBB disruption induced by peripheral T cell and neutrophil infiltration after ischemic stroke. These findings reveal a novel endogenous protective mechanism against BBB damage with Serpina3n being a potential therapeutic target in ischemic stroke.
neurosciences,endocrinology & metabolism,hematology
What problem does this paper attempt to address?